Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Market Closed - Nyse Other stock markets 21:00:03 20/06/2025 BST			5-day change	1st Jan Change
154.73 ^USD	+0.08%		-1.38%	-21.26%

06-17	Baird Adjusts Price Target on IQVIA Holdings to $159 From $161, Maintains Neutral Rating	MT
06-11	IQVIA Launches New AI Agents for Life Sciences and Healthcare	CI

IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Published on 14/05/2024 at 17:20

Presenter Speech
Michael Ryskin (Analysts)

Okay. Great. We'll take things off. Thanks, everyone, for your patience, running a few minutes late here. But thanks, everyone, for coming. My name is Mike

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Iqvia Holdings Inc.

Baird Adjusts Price Target on IQVIA Holdings to $159 From $161, Maintains Neutral Rating	06-17	MT
IQVIA Launches New AI Agents for Life Sciences and Healthcare	06-11	CI
IQVIA Prices $2 Billion Senior Notes Due 2032	06-02	MT
IQVIA Announces Pricing Of Senior Notes	06-02	RE
Iqvia Plans $2 Billion Notes Offering	06-02	MT
Iqvia Announces Offering Of Senior Notes	06-02	RE
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Rifaximin Tablets, 550 Mg	06-02	CI
Claritev Corporation Appoints Mohamed Ramzy as SVP and General Manager, International	05-28	CI
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf	05-27	RE
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf	05-27	CI
Trump's Tariff Blitz Roils Markets, Targets EU and Apple	05-23
Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $188 From $255, Maintains Buy Rating	05-23	MT
Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…	05-23
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials	05-16	CI
IQVIA Teams Up With SCRI to Expedite Development of New Cancer Therapies	05-16	MT
IQVIA And SCRI Collaborate To Accelerate Global Oncology Trials	05-16	RE
Mizuho Adjusts Price Target on IQVIA Holdings to $190 From $210, Maintains Outperform Rating	05-15	MT
Lupin Limited Receives Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 10 Mg, 15 Mg	05-15	CI
IQVIA Holdings Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 02:20 PM	05-13
Morgan Stanley Adjusts Price Target on IQVIA Holdings to $185 From $250, Maintains Overweight Rating	05-08	MT
London Calling: Markets Jump	05-08
Analyst recommendations: AMD, Walt Disney, Applovin, Ionq, Uber...	05-08
About Doves and Deals	05-07
Stephens Adjusts Price Target on IQVIA Holdings to $200 From $250, Maintains Overweight Rating	05-07	MT
Citigroup Adjusts Price Target on IQVIA Holdings to $160 From $210, Maintains Neutral Rating	05-07	MT